Biofidelity's mission is to enable the early detection of disease and to improve patient outcomes through the implementation of simple yet ultra-high sensitivity diagnostic assays based on Biofidelity’s proprietary biochemistry

Biofidelity

  • The company

    • Experienced Leadership Team

    • Heiner Dreismann, former President and CEO of Roche Molecular Systems, is Chairman. Dr Dreismann was a pioneer in the early adoption of PCR technologies.

    • Founded in 2019 in Cambridge, but also include both a U.S. headquarters and state-of-the-art clinical cancer diagnostic laboratory located in Research Triangle Park, North Carolina.

  • The Technology

    • Biofidelity’s platform technology enables precision genomic testing to be carried out far more simply, rapidly, and affordably.

    • It can be deployed in local hospital laboratories using the same PCR equipment used for COVID testing, addressing systemic problems in the market and making precision testing globally accessible, with the potential to transform millions of lives.

  • The Market

    • The company is working with leading medical centres and diagnostics providers in the US to validate its first product, with launch targeted in H1 2023.

    • Its technologies can be deployed across multiple verticals in human health, with a combined TAM of >$100bn, and are highly differentiated from competing approaches.

  • Current stage

    • Biofidelity raised $23M in Series A+ Financing (led by Octopus Ventures) in July 2022

    • Biofidelity is currently raising a $50m financing to fund the launch of its first products, scaling of operations to meet customer demand, and development of a product portfolio.

Investor presentation